首页> 外文期刊>Advanced Powder Technology: The internation Journal of the Society of Powder Technology, Japan >The impact of preparation parameters on sustained release aceclofenac microspheres: A design of experiments
【24h】

The impact of preparation parameters on sustained release aceclofenac microspheres: A design of experiments

机译:制备参数对缓释醋氯芬酸微球的影响:实验设计

获取原文
获取原文并翻译 | 示例
       

摘要

Polymeric (Ethylcellulose: Eudragit (R) RS100) microspheres containing aceclofenac was formulated by oil-in-water (o/w) single emulsion solvent evaporation method using response surface methodology. The amount of PVA and polymers in combination were selected as formulation variables and the speed of the stirrer as a process variable. The resultant microspheres were characterized for their size, morphology, encapsulation efficiency (E.E.), and drug release. The physicochemical characteristics of microspheres were assessed operating field emission scanning electron microscopy, Fourier transform infrared spectroscopy (FTIR), and X-ray powder diffractometry (XRPD). The PVA and speed were identified as the significant factors determining the encapsulation efficiency of the microspheres. The E. E. range was from 60.86 +/- 0.76% to 84.07 +/- 0.88%, enhanced with the decrease in the amount of PVA and increase in speed of stirring. Optimized formulation of microspheres was prepared using optimal process variables setting in order to evaluate the optimization capability of the models generated according to IV-optimal design. The optimized microspheres formulation containing aceclofenac showed E. E. of 84.94 +/- 1.91 with small error value (0.88). The microspheres were found to be discrete, spherical with smooth surface. The absence of interaction between drug and polymer was confirmed by FTIR spectroscopy. The XRPD revealed the dispersion of drug within microspheres formulation. Sustained drug release profile (minimum; 18.55% - 62.79%; maximum) in 12 h was achieved by a combination of polymers. The results demonstrate that these microspheres could be promising delivery system to sustain the drug release and improve the encapsulation efficiency thus prolong drug action and achieve the highest healing effect with minimal gastrointestinal side effect. (C) 2014 The Society of Powder Technology Japan. Published by Elsevier B. V. and The Society of Powder Technology Japan. All rights reserved.
机译:含有醋氯芬酸的聚合物(乙基纤维素:Eudragit(R)RS100)微球通过水包油(o / w)单乳液溶剂蒸发法,使用响应表面方法配制。选择PVA和聚合物的组合量作为配方变量,并选择搅拌器的速度作为过程变量。对所得的微球的大小,形态,包封效率(E.E.)和药物释放进行表征。微球的理化特性通过工作场发射扫描电子显微镜,傅里叶变换红外光谱(FTIR)和X射线粉末衍射(XRPD)进行了评估。 PVA和速度被确定为决定微球包封效率的重要因素。 E.E.范围为60.86 +/- 0.76%至84.07 +/- 0.88%,随PVA量的减少和搅拌速度的增加而增强。使用最佳工艺变量设置来制备微球的优化配方,以便评估根据IV最佳设计生成的模型的优化能力。含有醋氯芬酸的优化微球制剂的E. E.为84.94 +/- 1.91,误差值很小(0.88)。发现微球是离散的,具有光滑表面的球形。 FTIR光谱证实了药物与聚合物之间不存在相互作用。 XRPD显示药物在微球制剂中的分散。通过聚合物的组合,在12小时内获得了持续的药物释放曲线(最小值; 18.55%-62.79%;最大值)。结果表明,这些微球可以成为维持药物释放和改善包封效率的有希望的递送系统,从而延长药物作用并以最小的胃肠道副作用实现最高的治愈效果。 (C)2014日本粉末技术学会。由Elsevier B. V.和日本粉末技术学会出版。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号